ILIAS Biologics Inc.

ILIAS Biologics Inc. is a pioneering company in the biopharma and biotechnology industries, founded in 2015 and headquartered in South Korea. The company boasts a strong commitment to revolutionizing human medicine through the development of engineered exosomes with their proprietary platform technology, EXPLOR®. These engineered exosomes enable the delivery of therapeutic proteins to previously untargetable intracellular pathways, offering a potential solution for life-threatening and rare diseases. ILIAS Biologics recently secured a significant $20.60M Series B investment on 28 September 2020, with contributions from a consortium of notable investors including Asset One, Daedeok Venture Partners, Daishin Securities, Devsisters Ventures, Genie Asset Management, HB Investment, Meritz Securities, Timefolio Asset Management, Kiwoom Investment, and 한양증권(주). ILIAS Biologics' groundbreaking work in exosome-based therapeutics positions them as a global leader in the field, with an expanding network of research and business partnerships driving their potential to redefine the treatment landscape for rare diseases. To learn more about their innovative approach, visit their website at http://www.iliasbio.com or contact them via email at [email protected].